Time is running out for CureVac investors as the company’s acquisition by BioNTech enters its final phase. The window for shareholders to exchange their holdings is rapidly closing, creating urgency around complex procedural deadlines that could determine participation in the newly forming biotechnology alliance.
Share Exchange Mechanics Demand Early Action
While the official tender offer period extends until December 3, investors must account for crucial operational timelines. Financial institutions processing the transactions require additional days for settlement procedures. Market participants are strongly advised to submit their CureVac shares for exchange by Tuesday, December 2 at 6:00 PM EST (early Wednesday morning in European time zones).
Missing this practical cutoff could prevent timely processing by depositories, potentially excluding shares from the initial conversion phase. Investors who delay beyond this point face uncertainty about when their holdings might be incorporated into the merger structure.
Regulatory Hurdles Cleared for Combination
The path toward consolidation appears firmly established after shareholders demonstrated overwhelming support during the extraordinary general meeting. An impressive 99.16 percent of represented votes endorsed the offer and accompanying corporate restructuring. Germany’s Federal Cartel Office has also granted regulatory approval, eliminating what often represents a prolonged obstacle in such transactions.
Should investors sell immediately? Or is it worth buying CureVac?
The deal’s completion now hinges primarily on achieving the minimum acceptance threshold. BioNTech requires tender of 80 percent of outstanding CureVac shares, though provisions allow for reducing this requirement to 75 percent under certain conditions. The fixed exchange ratio of 0.05363 BioNTech shares for each CureVac security directly links the Tübingen-based company’s fate to the Mainz vaccine developer’s market performance.
Trading Activity Signals Market Confidence
Recent market behavior indicates strong belief in the merger’s successful completion. During the abbreviated Black Friday trading session, volume surged to over 5 million shares—multiple times the normal daily average. This activity suggests arbitrage traders and institutional investors are establishing significant positions to capture remaining price discrepancies.
CureVac shares concluded Friday’s session at €4.68, hovering near their 52-week peak. The stock’s proximity to the calculated value of the acquisition offer reflects market consensus that the transaction will proceed as planned.
Strategic Considerations for Equity Holders
Traditional fundamental metrics, including theoretical liquidity extending to 2028, have become largely irrelevant in the current context. The share price has decoupled from pipeline developments and now moves primarily according to merger mechanics. For shareholders, the decision has shifted from whether to buy or sell to whether to exchange now or wait—with the latter approach carrying increasing risk as Tuesday’s operational deadline approaches.
Ad
CureVac Stock: Buy or Sell?! New CureVac Analysis from November 29 delivers the answer:
The latest CureVac figures speak for themselves: Urgent action needed for CureVac investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 29.
CureVac: Buy or sell? Read more here...
